Moxalactam disodium (LY 127935) and cefotaxime (HR-756) are two new semisynthetic beta-lactam antibiotics. Moxalactam is structurally unique among beta-lactam compounds in that an oxygen molecule has been substituted for sulfur in the cephem nucleus (1) . Thus, the compound is properly termed a 1-oxa-beta-lactam antibiotic. Cefotaxime, on the other hand, is a highly beta-lactamase-resistant semisynthetic cephalosporin (3) . Initial reports (1, (4) (5) (6) indicate that both compounds possess an extremely broad spectrum, which includes aerobic gram-positive cocci, Enterobacteriaceae, Pseudomonas aeruginosa, Haemophilus influenzae, and certain anaerobes. The present study compares the activities of both moxalactam and cefotaxime with other currently available antibiotics against normally cephalosporin-resistant members of the Enterobacteriaceae, Pseudo Moxalactam and cefotaxime were the most active agents tested against 10 isolates of Citrobacter freundii (MICs ' 1 Ag/ml). Cefamandole and cefuroxime were the next most active agents, followed by cefoxitin and cephalothin. Moxalactam and cefotaxime were essentially equivalent in activity against Enterobacter aerogenes and Enterobacter cloacae (MICs '. 4 ,g/ ml). Cefamandole and cefuroxime were the next most active against Enterobacter spp., whereas cefoxitin and cephalothin failed to demonstrate inhibition of these isolates. Moxalactam and cefotaxime were the most active agents tested against 12 isolates ofgentamicin-susceptible Serratia marcescens, which were not effectively inhibited by the remaining beta-lactam drugs.
Results of testing selected gentamicin-resistant Enterobacteriaceae are shown in Table 2 . Eleven isolates of Escherichia coli were inhibited by 0.125 ytg of either moxalactam or cefotaxiime per ml. The remaining beta-lactam antibiotics and amikacin demonstrated rela- (Table 5) , all isolates were uniformly susceptible to the new compounds and the currently available antibiotics. Exceptions were observed in the relative insusceptibility of Aeromonas hydrophila to cephalothin and carbenicilhin and the relative resistance of the Vibrio spp. to carbenicillin. a cephalosporin, but rather as a new 1-oxa-betalactam antibiotic. In our study, both of these new compounds showed striking in vitro activity against the Enterobacteriaceae and good activity against P.
aeruginosa. Moxalactam and cefotaxime were shown to have similar activities against most of the organisms included in this study. However, several interesting differences occurred in which one of the two agents appeared markedly more active than the other. Cefotaxime seemed superior against P. maltophilia, P. putida, P. diminuta, Acinetobacter Iwoffi, and P. fluorescens.
Mosalactam appeared somewhat more active against A. xylosoxidans, C. terrigena, A. odorans, B. bronchiseptica, and CDC IVC-2.
It is noteworthy that both moxalactam and cefotaxime were comparable to or more active than carbenicillin against pseudomonads and other nonfermentative organi . The action of these new compounds against 22 isolates of multiply resistant S. marcescens was particularly encouraging. The ability of both antibiotics to act synergistically with amikacin against the majority of Serratia isolates and to produce at least an additive effect against most P. aeruginosa isolates further amplifies the potential usefulness of these new beta-lactam antibiotics. 
